ArticleMolecular biology reports2026
Exploring the therapeutic potential of crocin, a bioactive component of saffron, in neurocognitive deficit and pulmonary impairment induced by inhalational exposure to petroleum vapours.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term recurrent exposure to petroleum fumes poses a substantial occupational risk, specifically among individuals in gasoline stations. They are routinely exposed to the inherent toxic constituents of petrol and diesel, such as hydrocarbons, VOCs, and trace elements, during their routine activities, including fuel dispensing, handling, storage, transport, and refining processes. Due to inadequate safety measures allow these toxicants into the lungs, cross the pulmonary barrier, enter the circulation and subsequently reach the brain through disrupting the lung-brain axis (LBA). The present study aims to investigate the sub-chronic effects of petrol and diesel fumes on respiratory and neurocognitive functions, along with therapeutic efficacy of saffron-derived bioactive constituent, crocin (10 mg/kg, i.p.), as a potential neuroprotective agent.
methodsThe pulmonary dysfunctions were estimated by cytokine analysis in the broncho-alveolar lavage fluid (BALF), antioxidant activity, Evans blue dye (EBD) extravasation for microvascular airway leakage and histology analysis. Neurocognitive impairments were elucidated by behavioural paradigm, along with determination of acetylcholinesterase activity (AChE), antioxidant levels, protein biomarkers and EBD vascular permeability assay for blood-brain-barrier (BBB) permeability, neuronal count and histopathological examination.
resultsIntraperitoneal administration of crocin was found to attenuate anxiety-like behaviour and improve associative memory following intoxication with petroleum fumes. These effects are accompanied by enhanced antioxidant defence (SOD, GSH, CAT) and reduced lipid peroxidation in both lungs and brain tissues. Additionally, crocin downregulates the expression of amyloid precursor protein (APP) (p < 0.05) in DE animals, thereby preserving capillary barrier integrity and BBB permeability. Histopathology results confirmed that crocin can prevent alveolar damage and inflammatory cell infiltration, while improve neuronal integrity and increasing neuronal density in the hippocampus.
conclusionThese findings indicate partial protection of the pulmonary and neurological systems with crocin. However, no significant effects were observed on the spatial memory, cytokine levels and APP expression at the tested dose. Therefore, future studies are warranted to optimise the dosing regimen of crocin for preventing petroleum product-induced pulmonary and neurological complications.
Indexed as
Identifiers
41632349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.